Cargando…

Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients

Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for therapy management in oncology. We aimed to establish a multimodal liquid biopsy strategy that is usable with minimized blood volume to deconvolute the genomic complexity of metastatic breast cancer. CTCs were isola...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keup, Corinna, Storbeck, Markus, Hauch, Siegfried, Hahn, Peter, Sprenger-Haussels, Markus, Hoffmann, Oliver, Kimmig, Rainer, Kasimir-Bauer, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281124/ https://www.ncbi.nlm.nih.gov/pubmed/32349306 http://dx.doi.org/10.3390/cancers12051084

Ejemplares similares

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Keup, Corinna, et al.
Publicado: (2019)

Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer
por: Keup, Corinna, et al.
Publicado: (2021)

Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
por: Keup, Corinna, et al.
Publicado: (2019)

Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients
por: Keup, Corinna, et al.
Publicado: (2021)

Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple‐negative breast cancer patients
por: Bittner, Ann‐Kathrin, et al.
Publicado: (2020)

Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
por: Keup, Corinna, et al.
Publicado: (2023)

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
por: Moukas, Stefanos Ioannis, et al.
Publicado: (2023)

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy
por: Chebouti, Issam, et al.
Publicado: (2017)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2022)

Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma
por: Grölz, Daniel, et al.
Publicado: (2018)

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer
por: Bredemeier, Maren, et al.
Publicado: (2017)

Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients
por: Mach, Pawel, et al.
Publicado: (2021)

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
por: Chebouti, Issam, et al.
Publicado: (2016)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2009)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2012)

Anti-Mullerian-hormone levels during pregnancy and postpartum
por: Köninger, Angela, et al.
Publicado: (2013)

Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
por: König, Lisa, et al.
Publicado: (2019)

Optimized Quantification of Fragmented, Free Circulating DNA in Human Blood Plasma Using a Calibrated Duplex Real-Time PCR
por: Horlitz, Martin, et al.
Publicado: (2009)

Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
por: Hoffmann, Oliver, et al.
Publicado: (2022)

Evaluation of a novel ELISA for the tumor-associated antigen CA 72–4 in patients with ovarian cancer
por: Buderath, Paul, et al.
Publicado: (2016)

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
por: Bredemeier, Maren, et al.
Publicado: (2016)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Image-Based Identification and Genomic Analysis of Single Circulating Tumor Cells in High Grade Serous Ovarian Cancer Patients
por: Salmon, Carolin, et al.
Publicado: (2021)

CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis
por: Kallergi, Galatea, et al.
Publicado: (2020)

Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2021)

Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome
por: Köninger, Angela, et al.
Publicado: (2014)

Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients
por: Hoffmann, Oliver, et al.
Publicado: (2023)

Systematic Evaluation of HLA-G 3’Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome
por: Rebmann, Vera, et al.
Publicado: (2022)

Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer
por: Schwich, Esther, et al.
Publicado: (2019)

HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer
por: Schwich, Esther, et al.
Publicado: (2019)

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
por: Mairinger, Fabian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s8uf5uruirq21pf8hm45p58gef